Alunbrig scores NICE backing for ALK-positive lung cancer
ALK inhibitor recommended in the first-line non-small cell lung cancer setting
Read More
Tag: Alunbrig
New US approval for Takeda’s Alunbrig
The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC
Read More
Expanded EU approval for Takeda’s Alunbrig
The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option
Read More
Alunbrig recommended by NICE for non-small-cell lung cancer
NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.
Read More
EU green light for Takeda’s Alunbrig
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.
Read More
Preliminary NICE ‘no’ for Takeda’s Alunbrig
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Read More
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read More
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read More
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read More
Takeda’s lung cancer drug approved in the US
Takeda Pharmaceuticals has bagged approval for Alunbrig in the US as a treatment for a specific group of lung cancer patients.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
